Sulphinpyrazone

Sulphinpyrazone is a sulfoxide analogue of phenylbutazone. Sulphinpyrazone is used as an uricosuric agent. Sulphinpyrazone is organic acid and act at the anionic transport sites of the renal tubule. Sulphinpyrazone is employed to decrease the body pool of urate in patients with tophaceous gout or in those with frequent gouty attacks. Sulphinpyrazone is not used for acute attacks of gout. It has been studied as an antithrombotic agent.

Sulphinpyrazone is primarily indicated in conditions like Gout prophylaxis, Infertility without hyperprolactinemia, Mild to moderate endometriosis.

Sulphinpyrazone is contraindicated in conditions like Gout, Peptic ulcer, Renal failure, Nephrolithiasis, Hepatic disease.

The severe or irreversible adverse effects of Sulphinpyrazone, which give rise to further complications include Hematuria, Renal colic, Bleeding from pre-existing ulcer disease. Sulphinpyrazone produces potentially life-threatening effects which include Blood dyscrasias. which are responsible for the discontinuation of Sulphinpyrazone therapy. The symptomatic adverse reactions produced by Sulphinpyrazone are more or less tolerable and if they become severe, they can be treated symptomatically, these include Nausea, Skin rashes, Epigastric discomfort.

Sulphinpyrazone should be used only when clearly needed during pregnancy or lactation. Avoid alcohol while taking this drug.

Drug should not be given to Paediatrics, patients suffering from Kidney dysfunction, patients suffering from Liver Malfunction, Geriatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

0.48 to 0.95 mg/kg (0.72 (0.715)) 8 hourly PO — Initially for 2-3 Weeks 2.86 to 3.81 mg/kg (3.3 (3.335)) 8 hourly PO — Maintenance

No child dosage information is recorded for this medicine yet.

No neonatal dosage information is recorded for this medicine yet.

Sulphinpyrazone is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAllopurinolAminophyllineAspirinAspirin antagonizes effects of Sulphinpyrazone.Choline Magnesium TrisalicylateFosphenytoinNicoumaloneNicoumaloneNitrofurantoinOxtriphylline (Choline Theophyllinate)ParacetamolSulphinpyrazone increases the hepatotoxicity of paracetamol and decreases its pharmacological effect by accelerating the metabolism of paracetamol.ModerateUse of this combination should be avoided over a prolong period of time. Closely monior for hepatotoxicity.PhenindionePhenytoin (Na)ProbenecidPyrazinamideSulfapyridineThe effects of Sulphinpyrazone may be potentiated during concurrent use with sulfonamides because of displacement from plasma protein-binding sites.SulphamethizoleSulphinpyrazone may displace sulfonamides from plasma protein binding sites, increasing sulfonamide concentrations.TheophyllineTheophyllineSulphinpyrazone increases the clearence of theophylline by 22% by increasing metabolism and decreasing its renal clearence.MinorClosely monitor the serum level of theophylline. Patient should report the worsening of respiratory symptoms to physician.Tinzaparin SodiumConcurrent use may increase the risk of bleeding.If coadministration is essential, close clinical and laboratory monitoring of these patients is advised.TolbutamideWarfarin (Na)Sulphinpyrazone may decrease the metabolism of Warfarin.ModerateMonitor for increased effects of Warfarin if Sulphinpyrazone is initiated/dose increased, and decreased effects if Sulphinpyrazone is discontinued/dose decreased. These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Tab Store Below 25°C. Protect from Moisture.